abrdn plc Boosts Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

abrdn plc raised its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 187,180 shares of the biotechnology company's stock after purchasing an additional 28,967 shares during the period. abrdn plc owned about 0.31% of Ascendis Pharma A/S worth $25,769,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Ascendis Pharma A/S by 14.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,789 shares of the biotechnology company's stock valued at $1,761,000 after buying an additional 1,647 shares during the period. Gilbert & Cook Inc. raised its holdings in Ascendis Pharma A/S by 72.5% in the 4th quarter. Gilbert & Cook Inc. now owns 4,421 shares of the biotechnology company's stock valued at $609,000 after acquiring an additional 1,858 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Ascendis Pharma A/S by 540.5% during the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock worth $76,000 after purchasing an additional 427 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Ascendis Pharma A/S by 410.4% during the fourth quarter. SG Americas Securities LLC now owns 33,944 shares of the biotechnology company's stock worth $4,673,000 after purchasing an additional 27,293 shares during the last quarter. Finally, ARS Investment Partners LLC boosted its holdings in shares of Ascendis Pharma A/S by 0.9% during the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company's stock worth $36,549,000 after purchasing an additional 2,369 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ASND shares. Oppenheimer reduced their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. TD Cowen lowered their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Wedbush reiterated an "outperform" rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $191.57.

Ascendis Pharma A/S Trading Down 3.3 %

Shares of ASND traded down $4.15 during midday trading on Friday, reaching $120.87. 414,464 shares of the company were exchanged, compared to its average volume of 433,669. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The stock has a 50-day moving average price of $132.60 and a 200-day moving average price of $132.48.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.